LUNIS Biotech Growth Opportunities Fund I a Fonds
29,04
EUR
-0,49
EUR
-1,66
%
NAV
Werbung
Der Fonds LUNIS Biotech Growth Opportunities Fund I a Fonds wird seit dem 30.12.2024 nicht mehr vertrieben. Nähere Informationen erhalten sie von der Fondsgesellschaft.
Top Holdings
| Name | ISIN | Anteil |
|---|---|---|
| XOMA Royalty Corp | US98419J2069 | 9,54% |
| Denali Therapeutics Inc | US24823R1059 | 6,99% |
| NextCure Inc | US65343E1082 | 6,26% |
| TScan Therapeutics Inc | US89854M1018 | 6,14% |
| Amarin Corp PLC ADR | US0231112063 | 5,58% |
| Heron Therapeutics Inc | US4277461020 | 5,40% |
| Athira Pharma Inc Ordinary Shares | US04746L1044 | 5,09% |
| Prelude Therapeutics Inc Ordinary Shares | US74065P1012 | 4,84% |
| Olema Pharmaceuticals inc Ordinary Shares | US68062P1066 | 4,46% |
| Aldeyra Therapeutics Inc | US01438T1060 | 4,43% |
| Sonstige | 41,26% |